Clinical Trials Logo

Ischemic Stroke clinical trials

View clinical trials related to Ischemic Stroke.

Filter by:

NCT ID: NCT03649711 Completed - Clinical trials for Chronic Kidney Diseases

Chronic Kidney Disease (CKD) Platelet Study

Start date: November 1, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration will be two weeks. After recruiting CKD participants the investigator will recruit controls with normal kidney function that will receive only ticagrelor and aspirin for two weeks.

NCT ID: NCT03629652 Terminated - Ischemic Stroke Clinical Trials

Head-dOwn Position for ischEmic Stroke With Middle Cerebral Artery (HOPES)

HOPES
Start date: August 6, 2018
Phase: N/A
Study type: Interventional

The study is designed to explore the efficacy and safety of head-down position in patients with acute ischemic stroke。

NCT ID: NCT03629275 Terminated - Ischemic Stroke Clinical Trials

Investigation of Neural Stem Cells in Ischemic Stroke

PISCES III
Start date: August 31, 2018
Phase: Phase 2
Study type: Interventional

A study of stereotactic, intracerebral injection of CTX0E03 neural stem cells into patients with moderate to moderately severe disability as a result of an ischemic stroke.

NCT ID: NCT03620370 Completed - Stroke, Acute Clinical Trials

Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke

Start date: August 12, 2018
Phase: N/A
Study type: Interventional

NBO is a nonpharmacological measure of neuroprotection. The purpose of our study is to evaluate the safety and efficiency of NBO(Normobaric hyperoxia) in the acute ischemic stroke patients who received endovascular treatment. Looking for more clinical evidence for the ischemic stroke patients who will be treated with NBO in the future.

NCT ID: NCT03609385 Completed - Clinical trials for Acute Coronary Syndrome

PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE

PRAISE
Start date: August 1, 2018
Phase:
Study type: Observational

The primary goal of the PRAISE study is to develop a diagnostic algorithm that allows the prediction of acute coronary syndrome in stroke patients with elevated levels of cardiac troponin.

NCT ID: NCT03608904 Recruiting - Ischemic Stroke Clinical Trials

Stroke Recovery and Music or No Music

Start date: July 21, 2017
Phase: N/A
Study type: Interventional

The primary outcome of this study is to determine the quantitative increase in connectivity, as measured by fMRI brain and calculated as a percent increase from baseline in patients with ischemic stroke. Eligible patients will receive a listening session of music or spoken word listening, 30 days to 5 years following ischemic stroke. Assessments will include modified Rankin Scale, National Institute of Health Stroke Scale, functional Magnetic Resonance Imaging, motor function tests, and neuropsychological evaluations. Assessments occur at baseline, day 45, and day 90 after starting listening sessions.

NCT ID: NCT03602326 Completed - Ischemic Stroke Clinical Trials

Neurodevelopmental Therapy-Bobath Approach in The Early Term of Stroke; Safe and Effective

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

Early term rehabilitation initiated after stroke should be based on motor learning principles and neural plasticity. To achieve motor learning and neural plasticity, exercises consisting of intense and repetitive training should be given according to the patients' functional level. The neurodevelopmental treatment-Bobath (NDT_B) approach is based on motor learning principles. In literature, studies that show the early term effects of NDT-B on functional recovery are inadequate. The aim of this study was to investigate the effects NDT-B applied in the early term of stroke, on postural control, functional movement, balance and activities of daily living.

NCT ID: NCT03601702 Recruiting - Clinical trials for Acute Ischemic Stroke

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.

NCT ID: NCT03596502 Completed - Atrial Fibrillation Clinical Trials

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)

Start date: February 1, 2018
Phase:
Study type: Observational

The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) and warfarin for stroke prevention in patients with non-valvular atrial fibrillation (AF). The comparison of DOACs versus oral vitamin K antagonists, in particular warfarin, is of interest. The investigators will carry out separate population-based, matched cohort studies, using health administrative databases in seven Canadian provinces. New users of oral anticoagulants (DOACs or warfarin) for stroke prevention in non-valvular AF will be eligible to enter the cohorts. Follow-up will continue until a hospitalization or emergency department visit for a stroke. The results from the separate sites will be combined by meta-analysis to provide an overall assessment of the safety and effectiveness of the different anticoagulation regimens in stroke prevention in AF. The investigators hypothesize that DOACs and warfarin will have similar safety and effectiveness profiles.

NCT ID: NCT03592563 Recruiting - Stroke Clinical Trials

CUHK Brain Health Longitudinal Study

BHS
Start date: July 1, 2019
Phase:
Study type: Observational

The goal of this study is to develop a large longitudinal cohort of individuals diagnosed with or at high risk for brain diseases (both neurological and psychiatric in nature), in order to identify risk factors that contribute to neurological and psychiatric diseases over time. The investigators seek to capture relevant information from medical records, electronically administered questionnaires and follow up phone-based interviews. The investigators expect to eventually have sufficient power from our dataset to examine risk factors for a variety of brain disorders, both individually and in aggregate. Our ultimate goal is to offer scientifically validated ways to preserve and promote brain health by working with our patients' needs and tracking their progress over time.